Hosted on MSN12d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
UPI14d
FDA approves Spravato, first monotherapy nasal spray to treat depression
Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...
drugtargetreview.com1d
Promising Alzheimer’s drug earns FDA fast-track designation
Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...
NJBIZ14d
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, health care providers have had few ...
Why Johnson & Johnson’s CEO Welcomes Scrutiny
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
Trump administration pauses communication from CDC, other health agencies
The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...